【摘要】 目的 探讨蛛网膜下腔出血(subarachnoid hemorrhage,SAH)后应用尼莫地平与再出血的关系,以指导临床合理用药。方法 以307例SAH患者为研究对象,按照确诊SAH给予尼莫地平的时间分为3组,尼莫地平Ⅰ组108例,在发病≤3 d时给予尼莫地平静脉滴注,每日1次,2周后改为口服尼莫地平片30 mg,每日3次;尼莫地平Ⅱ组96例,首次给予尼莫地平距发病时间>3d;对照组103例,确诊为SAH后不用尼莫地平治疗。观察3组再出血情况,进行统计学分析。结果 再出血率以尼莫地平Ⅰ组最低,对照组最高,对Hunt-HessⅡ级的SAH病例,尼莫地平Ⅰ组与对照组比较,x2=4.55,P<05,差异具有显著性意义。其他各组比较差异均无显著性。结论 早期使用尼莫地平预防SAH血管痉挛是安全的,不增加再出血率。更多还原

【Abstract】 Objective To study the effect of Nimotop on rebleeding after subarachnoid hemorrhage (SAH). Methods 307 in-hospital patients with SAH were studied. These cases were divided into three groups. The Nimotop group I,108cases, treated with Nimodipine(Nimotop) (iv)on early stage of SAH ( ≤ 3 d ), 1 time daily, 2 weeks later Nimotop tablets were given 30mg by oral, three times daily. The Nimotop group Ⅱ, 96 cases, treated with Nimotop (iv)3 days after haemorrhage, 2 weeks later Nimotop tablets 30 mg were given by oral, three times daily. The Control group was not treated with Nimotop. The rebleeding rates after SAH in three groups were studied. Results The rebleeding rate of the Nimotop group I was the lowest and the control group was the highest. For the cases of Hunt-Hess grade Ⅱ in the Nimotop I group, the rebleeding rate was significantly lower than that of the control group, (x2=4. 55, P<0. 05). There were no significant difference between other groups. Conclusion Nimotop did not increase the rebleeding rate after SAH and it is safe in prevention of vasospasm in SAH patients.更多还原